Takeda Pharmaceutical Company Limited (TAK) Earnings History
Turnaround26 years of earnings data (2000–2025) · Recovering earnings after a multi-year decline
Loading earnings history...
Takeda Pharmaceutical Company Limited (TAK) Earnings Overview
As of June 22, 2026, Takeda Pharmaceutical Company Limited (TAK) reported trailing twelve-month net income of $193.19B, reflecting +90.1% year-over-year growth. The company earned $61.82 per diluted share over the past four quarters, with a net profit margin of 4.3%.
Looking at the long-term picture, TAK's 5-year EPS compound annual growth rate (CAGR) stands at -11.8%, signaling declining earnings. The company achieved its highest annual net income of $376.00B in fiscal 2020.
Takeda Pharmaceutical Company Limited maintains positive profitability with a gross margin of 51.1%, operating margin of 12.0%, and net margin of 4.3%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including NVO ($121.96B net income, 33.1% margin), AZN ($10.39B net income, 17.5% margin), SNY ($7.81B net income, 16.7% margin), TAK has room to improve margins relative to the peer group. Compare TAK vs NVO →
TAK Earnings vs Peers
Earnings metrics vs comparable public companies
TAK Historical Earnings Data (2000–2025)
26 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $203.33B | +88.4% | $573.04B | $63.91 | 4.3% | 12.0% |
| 2024 | $107.93B | -25.1% | $342.59B | $33.62 | 2.4% | 7.5% |
| 2023 | $144.07B | -54.6% | $214.07B | $45.58 | 3.4% | 5.0% |
| 2022 | $317.02B | +37.8% | $490.50B | $100.97 | 7.9% | 12.2% |
| 2021 | $230.06B | -38.8% | $460.84B | $72.94 | 6.4% | 12.9% |
| 2020 | $376.00B | +749.9% | $509.27B | $119.48 | 11.8% | 15.9% |
| 2019 | $44.24B | -59.5% | $100.41B | $14.13 | 1.3% | 3.1% |
| 2018 | $109.13B | -41.6% | $204.97B | $34.78 | 5.2% | 9.8% |
| 2017 | $186.89B | +62.6% | $241.79B | $118.78 | 10.6% | 13.7% |
| 2016 | $114.94B | +43.4% | $155.87B | $73.13 | 6.6% | 9.0% |
| 2015 | $80.17B | +155.0% | $130.83B | $50.86 | 4.4% | 7.2% |
| 2014 | -$145.78B | -236.7% | -$129.25B | $-46.47 | -8.2% | -7.3% |
| 2013 | $106.66B | -18.7% | $139.27B | $67.47 | 6.3% | 8.2% |
| 2012 | $131.24B | +5.7% | $122.50B | $94.09 | 8.4% | 7.9% |
| 2011 | $124.16B | -49.9% | $265.03B | $78.63 | 8.2% | 17.6% |
| 2010 | $247.87B | -16.8% | $367.08B | $156.98 | 17.5% | 25.9% |
| 2009 | $297.74B | +27.0% | $420.21B | $188.57 | 20.3% | 28.7% |
| 2008 | $234.38B | -34.1% | $306.47B | $144.90 | 15.2% | 19.9% |
| 2007 | $355.45B | +5.9% | $423.12B | $209.49 | 25.9% | 30.8% |
| 2006 | $335.81B | +7.2% | $458.50B | $193.00 | 25.7% | 35.1% |
| 2005 | $313.25B | +12.9% | $402.81B | $176.74 | 25.8% | 33.2% |
| 2004 | $277.44B | -2.7% | $385.28B | $156.51 | 24.7% | 34.3% |
| 2003 | $285.26B | +5.0% | $371.63B | $160.93 | 26.3% | 34.2% |
| 2002 | $271.76B | +15.3% | $310.69B | $153.82 | 26.0% | 29.7% |
| 2001 | $235.66B | +60.5% | $281.24B | $133.51 | 23.4% | 28.0% |
| 2000 | $146.85B | - | $226.10B | $83.20 | 15.2% | 23.5% |
Download Data
Export TAK earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into TAK consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
26+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TAK — Frequently Asked Questions
Quick answers to the most common questions about buying TAK stock.
What is TAK earnings per share (EPS)?
TAK trailing twelve-month (TTM) diluted EPS is $61.82, reflecting +90.1% year-over-year growth. The 5-year EPS CAGR is -11.8%. Complete EPS history from 2000 to 2025 is available in the table on this page.
What is Takeda Pharmaceutical Company Limited's net income?
Takeda Pharmaceutical Company Limited (TAK) trailing twelve-month net income is $193.2B as of 2025. Earnings grew +90.1% year-over-year. Takeda Pharmaceutical Company Limited has been profitable for 11 consecutive years.
Is TAK profitable?
Yes, TAK is profitable with a TTM net income of $193.2B and a net profit margin of +4.3%. Takeda Pharmaceutical Company Limited has generated profits for 11 consecutive years.
What is TAK's earnings growth rate?
TAK compound annual EPS growth rates (CAGR): 1-Year: +90.1%, 3-Year: -14.1%, 5-Year: -11.8%, 10-Year: +2.3%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2000 to 2025.
What are TAK's profit margins?
Takeda Pharmaceutical Company Limited net profit margin is +4.3%, operating margin is +12.0%, and gross margin is +51.1%. Below-average margins reflect competitive or cost pressures. Return on Equity is +2.8%.
Is TAK growing earnings?
Yes, TAK earnings are accelerating — EPS growth of +90.1% exceeds the 5-year CAGR of -11.8%. TTM net income reached $193.2B. Earnings momentum is strengthening.
What was TAK's best earnings year?
Takeda Pharmaceutical Company Limited's highest annual net income on record is $376.0B, achieved in fiscal year 2020. Earnings history on this page spans 2000 to 2025 and includes all annual and quarterly figures.
What were TAK's earnings last quarter?
TAK's most recent reported quarter was Q4 2025. Net income was $-24.8B with diluted EPS of $-7.92. For a full breakdown of all quarters, see the quarterly earnings table on this page.